Cancer Cell Therapy

CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

- Expanded Access protocols for commercial CAR-T products manufactured of specification
- 3rd line CAR Therapies

Age < 65 Yrs
- CCT5045 EAP for Patients Receiving Lisoctagonale Maraleneul That is Non-conforming for Commercial Release
  - PI: Miklos Sponsor: Novartis

Age > 65 Yrs
- CCT5044 Phase II trial of Biostronic aCD19 & a-20 CD28 CAR-T
  - PI: Parveen Sponsor: Kite

CCT5016 Managed Access Program (MAP) CTL019 in ALL or DLBCL
- PI: Miklos Sponsor: Novartis

CCT5006 Expanded Access Aldocleagene Ciloleucel in Tx Relapsed/Refractory T-plant- ineligible Aggressive NHL
- PI: Miklos Sponsor: Kite

CCT5051 Phase I/II Anti-CD19 CAR-engineered Allogeneic GammaDelta T Cells +/- IL-2 in BCell Malignancies
- PI: Miklos Sponsor: Precision Bio

CCT5035 Phase I/II ALLO-501 (AntiCD19 Allogeneic CAR TCell Tx) Relapsed/Refractory (R/R) NHL or R/R CLL or Small Lymphocytic Lymphoma
- PI: Miklos Allogene

CCT5024 Phase I/II PBCAR20A-1 Relapsed/Refractory (R/R) NHL

CCT5029 Phase I/II Autologus CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
- PI: Muffy Stanford

CCT5042 Pilot 18F-F-AraC PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
- PI: Miklos Stanford

CCT5032 Phase II Anti-CD19 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory Large B-Cell Lymphoma
- PI: Miklos Sponsor: Kite Pharma

CCT5036 Phase II Lisoctagonale Ciloleucel +/- Rituximab or Lenalidomide in B-cell Lymphoma
- PI: Parveen Sponsor: Kite Pharma

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Observation Study
- Extension Study
- Immunotherapy
- Enrollment on Hold